Spravato Janssen CarePath Savings Program: Most eligible commercially insured patients may pay $10 per treatment with savings of up to $7150 per calendar year; for additional information contact the program at 877-227-3728. Available at: https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f2139612744 (last accessed January 2021).16. Johnson & Johnson Ltd. Press release on December 2019. Exp Clin Psychopharmacol 2015;23(1):1–21. Spravato Janssen CarePath Savings Program Rebate: Eligible commercially insured patients may submit a rebate request if the pharmacy does not accept the Savings Card; for additional assistance contact the program at 877-227-3728. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. “Esketamine nasal spray offers adults with MDD who are in need of urgent relief, an effective treatment to reduce their debilitating depressive symptoms. Your use of the information on this site is subject to the terms of our Legal Notice. Available for Android and iOS devices. Visit Website, Looking to reduce costs at the pharmacy counter? Buy Local; CBS 17 Cares – First Responders; Contests; Veterans Voices; Carolina Business; About Us. Phillip Mayfield becomes a victim of Christopher Duntsch. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. Available at: http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/ (last accessed January 2021).14. American Psychological Association (APA). Find patient medical information for Spravato nasal on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Cautions Concerning Forward-Looking Statements.This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SPRAVATO® (esketamine nasal spray). Spravato (esketamine) is a member of the miscellaneous antidepressants drug class and is commonly used for Depression, and Major Depressive Disorder. 800-652-6227 It includes self-image issues, difficulty managing emotions and behavior, and a pattern of unstable relationships.With borderline personality disorder, you have an intense fear of abandonment or instability, and you may have difficulty tolerating being alone. This Spravato price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies. 3) Patient enrollment: Patients in an outpatient setting must be enrolled in the REMS with their prescriber in order to receive SPRAVATO® treatment. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The British National Formulary (BNF) is the first choice for concise medicines information. According to Janssen, the benefit of Spravato plus comprehensive SOC on symptoms of MDD was apparent as early as four hours after the first dose. Learn more at www.janssen.com/emea. Initially 28 mg on day 1, then 28–84 mg twice weekly for weeks 1–4, then 28–84 mg once weekly for weeks 5–8, then 28–84 mg every 1–2 weeks from week 9 onwards, review continued treatment periodically, treatment is recommended for at least 6 months after depressive symptoms improve, all dose adjustments to be made in 28 mg increments. Cost-effectiveness of Spravato can limit its uptake in MDD market. Johnson & Johnson Medical Devices Companies, https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf, https://www.janssen.com/emea/sites/www_janssen_com_emea/files/spravatorv_esketamine_nasal_spray_approved_in_europe_for_adults_with_treatment-resistant_major_depressive_disorder.pdf, https://www.jnj.com/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief, https://www.jnj.com/janssen-announces-u-s-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior, http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/, http://www.who.int/news-room/fact-sheets/detail/depression, https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f2139612744. 2. Neuropsychiatric Dis Treat 2011;7(suppl 1):3–7. References1. Prices are for cash paying customers only and are not valid with insurance plans. Esketamine nasal spray is already authorised by the EC for use in combination with a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI), in adult patients with treatment-resistant major depressive disorder (TRD).7, *The Montgomery-Åsberg Depression Rating Scale (MADRS): A 10-item diagnostic questionnaire, that psychiatrists use to measure the severity of depressive episodes in patients with mood disorders†Professor Maurizio Pompili has been a paid consultant for Janssen. VIDEO 2:10 02:10. Ionescu D, et al. New Window. Help . SPRAVATO ® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Here are 10 ways to save money on prescription drugs, trazodone, sertraline, Lexapro, citalopram, Xanax, Zoloft, Cymbalta, Prozac. The benefit of esketamine nasal spray plus comprehensive SOC on symptoms of MDD was apparent as early as 4 hours after the first dose.4,5 The effectiveness of esketamine nasal spray in preventing suicide or in reducing suicidal ideation or behaviour was not demonstrated. This site is governed solely by applicable U.S. laws and governmental regulations. The patient must be a US citizen or legal resident. Please click below to continue to that site. Adverse events should be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com and to regulatory authorities. Opdivo/Cabometyx also demonstrated superior PFS (10.3 months versus 4.2 months) and ORR (55.9% versus 22%) in this patient population, compared to Sutent. Pay our discounted price online and receive free home delivery from our licensed US pharmacy or pickup at any of our 35,000+ participating pharmacies nationwide. Spravato is usually given 2 times per week at first, and then once every 1 to 2 weeks. Depression and Other Common Mental Health Disorders: Global Health Estimates, 2017. 2) Pharmacy certification: All pharmacies must be certified in the REMS in order to receive and dispense SPRAVATO®. In Study 2, a long-term maintenance study, the discontinuation rates because of an adverse reaction were similar for patients receiving SPRAVATO plus oral AD and placebo nasal spray plus oral AD in the maintenance phase, at 2.6% and 2.1%, respectively. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. SPRAVATO ™ uses the first new mechanism of action in decades to treat MDD. Greenbrook TMS Inc. (TSX: GTMS) ("Greenbrook" or the "Company"), today announced its third quarter 2020 ("Q3 2020") operational and financial results. Within each study, patients treated with esketamine nasal spray accompanied by comprehensive SOC had a statistically significant and clinically meaningful reduction in depressive symptoms (reduction from baseline Montgomery-Åsberg Depression Rating Scale [MADRS]* total score) at 24 hours after receiving the first dose compared to placebo nasal spray in combination with comprehensive SOC (p=0.006). This authorisation provides a new and innovative treatment option to this vulnerable population.”, This EC authorisation is valid in all 27 member states of the European Union as well as the EEA countries (Norway, Iceland and Liechtenstein), and Northern Ireland and Great Britain following the additional step of validation and processing of the baseline submission required following the end of the transition period post-Brexit. Canuso C, et al. Machado-Vieira R, et al. Co-payment assistance, patient support, and patient assistance programs are available for eligible patients. Contact program for details. Depression. Open All Questions. Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or This milestone makes esketamine nasal spray the first N-methyl-D-aspartate (NMDA) antagonist to be approved for patients with Major Depressive Disorder (MDD) in a psychiatric emergency 1–3 The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. World Health Organisation (WHO). Esketamine nasal spray Summary of Product Characteristics. Spravato is expensive, which is unfortunate since women who are poor are at greater risk of depression. We comply with the HONcode standard for trustworthy health information -, Drug class: miscellaneous antidepressants, Here are 10 ways to save money on prescription drugs, Must have no prescription coverage for needed medication, Medication must be for outpatient use only. For Adult. Borderline personality disorder is a mental health disorder that impacts the way you think and feel about yourself and others, causing problems functioning in everyday life. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Dosing information. World Health Organisation (WHO). Intl J Neuropsychopharmacol 2019;22(10):616–630. Available at: https://www.jnj.com/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief (last accessed January 2021).12. Esketamine is used as a nasal spray or by injection into a vein.. Esketamine acts primarily as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Johnson & Johnson Ltd. Press release on August 2020. “Many antidepressants are effective in treating depressive symptomatology but do not provide rapid relief for patients and can take weeks to achieve their full effect. #ketamine #tms #deeptms #brainsway #deeptmstherapy #suicide #suicideawareness #mentalhealth #mentalhealthawareness #houston #psychiatrist … International Classification of Diseases 11th Revision (ICD-11). Johnson & Johnson Seeks Expanded Use in Europe for Depression Nasal Spray Less than a month after first getting approved in Europe, Janssen is continuing to grow in the continent. Pharmaceuticals 2010;3(1):19–41. Spravato offers may be in the form of a printable coupon, rebate, savings card, trial offer, or free samples. Note: All new enrollment is now done electronically or over the phone. Eligibility requirements vary for each program. The sessions are repeated twice weekly for 4 weeks, then once weekly for the next 4 weeks, and as needed thereafter. All contents © Copyright Johnson & Johnson Services, Inc.1997-2020. Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. Patients will remain in clinic for 2 hours and may not drive for 24-hours after treatment due to cognitive side effects. What is this medicine? If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Search. Spravato will cost between $4,720 and $6,785 before insurance during the first month of treatment, and between $2,360 and $3,540 in following months. European Medicines Agency (EMA) 6.2 FDA Medication Guides. Spravato is a nasal spray based on the drug ketamine, which has been used as an anesthetic for over half a century since its introduction in the … Important: When there is a range of pricing, consumers should normally expect to pay the lower price. World Health Organisation (WHO). NDC Code(s): 49396-0280-2, 49396-0280-3 Packager: Renaissance Lakewood LLC < previous | page of 1 | next > Why is DailyMed no longer displaying pill images on the Search Results and Drug Info pages? About Major Depressive Disorder Major depressive disorder (MDD) affects nearly 40 million people of all ages in Europe and is one of the leading causes of disability worldwide.13,14 Individuals with depression, including MDD, experience continuous suffering from a serious, biologically-based disease, which has a significant negative impact on all aspects of life, including quality of life and function.15,16 At its worst, MDD can be fatal, with MDD patients demonstrating a 20-fold higher risk of suicide than the rest of the population.17 Despite treatment advances, currently available antidepressant medications can take between four to six weeks to reach their full effect, and one-third of people who suffer from MDD do not respond to these treatments.18,19. FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults with treatment-resistant depression More information please phone: 877-227-3728 The site you’re being redirected to is a branded pharmaceutical website. (esketamine) He has not been compensated for any media work, About SPRAVATO® As an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, SPRAVATO® (esketamine nasal spray) offers the first new approved mechanism of action in 30 years for an antidepressant.1–3,9, Esketamine nasal spray is self-administered, under the direct supervision of a healthcare professional, through a single-use nasal spray device, offering a novel mode of drug administration for the treatment of patients within the licensed indications. Spravato (esketamine) This site uses cookies as described in our. Some offers may be printed right from a website, others require registration, completing a questionnaire, 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions. 800-675-8416 24-05-2019. 19. Die Pharmasparte des US-Konzerns Johnson & Johnson hat von der Europäischen Kommission die Zulassung für ihr esketaminhaltiges Nasenspray Spravato zur … Diagnostic and Statistical Manual of Mental Disorders. RCC with sarcomatoid differentiation is a highly aggressive form of the disease, and is typically associated with a particularly poor prognosis. **Please call 1-800-652-6227 or visit Program website for specific FPL income requirements. Fedgchin M, et al. The comprehensive SOC was enhanced by twice-weekly visits with extensive clinical contact, and concomitant use of benzodiazepines was permitted during the study.4,5. Available at: http://www.who.int/news-room/fact-sheets/detail/depression (last accessed January 2021).15. Mind Medicine is currently the only company in phase-2 clinical development of a non-toxic and well-tolerated Ibogaine congener - 18-MC. Visit Website. Esketamine is only given in a healthcare setting, such as a clinic or hospital. Do Not Sell My Personal Information; Search. Presented at 58th Annual Meeting of Neuropsychopharmacology (ACNP); December 2019.7. These studies compared the efficacy and safety of esketamine nasal spray in combination with comprehensive standard of care (SOC) against placebo nasal spray in combination with comprehensive SOC in adult patients with moderate to severe MDD and current/active suicidal ideation with intent.4,5 The comprehensive SOC included initial psychiatric hospitalisation and newly initiated or optimised oral antidepressant therapy, which was determined by the treating physician based on clinical judgement and practice guidelines, for the duration of the studies. J Clin Psychiatry 2020;81(3):19m13191. Your healthcare provider will check your blood pressure before taking SPRAVATO ® and for at least 2 hours after you take SPRAVATO ®. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Blink Health is driving down the cost of prescription drugs in America with up to 80% savings on prescription medications. Int J Neuropsychopharmacol 2020;pyaa068. 6. 5th Ed. Your doctor will tell you how often you need to use the medicine. Spravato 866-228-3546 Following the recent US Food and Drug Administration approval of Spravato (esketamine) nasal spray, from… CNS Diseases Focus On Janssen Johnson & Johnson Neurological Pharmaceutical Pricing, reimbursement and access Psychoactive drugs Spravato USA 18. 866-316-7263 Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. The safety profile for esketamine nasal spray in this patient population was consistent with previous studies in adults with treatment-resistant major depressive disorder (TRD).1,8 The most common treatment-emergent adverse events (≥20%) observed in the esketamine nasal spray plus comprehensive SOC group versus the placebo nasal spray plus comprehensive SOC group during the double-blind phase were dizziness (38.3% vs 13.8%), dissociation (33.9% vs 5.8%), nausea (26.9% vs 13.8%), somnolence (20.7% vs 10.2%), and headache (20.3% vs 20.4%), respectively.6, “At Janssen, we are committed to reducing the devastating burden caused by serious mental illnesses and this further authorisation of esketamine nasal spray by the European Commission is a key milestone in our ongoing work towards this goal,” said Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. Duman RS, et al. Select one or more newsletters to continue. discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. Fu DJ, et al. Adverse events should be reported. The fast-acting nature of esketamine nasal spray in these patients may address a key unmet need within this population.”, The EC authorisation of esketamine nasal spray is based on data from the Phase 3 double-blind, randomised, placebo controlled, multicentre ASPIRE I & II clinical studies conducted globally. Intranasal esketamine is administered under the SPRAVATO REMS program as required by the FDA and the manufacturer Janssen Pharmaceuticals. Generic Name: esketamine hydrochloride Brand Name: Spravato Manufacturer: Janssen Inc. Visit Website, More information please phone: SPRAVATO (esketamine hydrochloride) solution. 1,2,3 SPRAVATO™ works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor in … Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Versandapotheke, Internet-Apotheke: Online Apotheke Rezept einsenden & Vorteile sichern Versandkostenfrei bei Rezepten & ab 19€ Rezeptfreie Medikamente günstig bestellen Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. or obtaining a sample from the doctor's office. The cost for Spravato nasal spray 28 mg is around $687 for a supply of 2 spray, depending on the pharmacy you visit. The patient must also be residing in the US. Remarkable Women of 2021; TV Schedule ; Rescan; Meet the CBS 17 team; Contact Us; Work With Us; CBS 17 news and weather apps; Daily newsletter; Contests; Viewer Feedback Panel; Advertise with CBS 17; Got a tip? All Rights Reserved. Dialogues Clin Neurosci 2015;17(2):111–126. European Medicines Agency. Popova V, et al. For further safety information, please see the Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf. The patient must also be permanently residing in the US or US territories. Follow us at www.twitter.com/JanssenEMEA. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Am J Psych 2019;176:428–438. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. Nat Med 2016;22(3):238–249.3. You are now leaving jnj.com. In February 2021, the vaccine received emergency authorization in … None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. Esketamine (Es KEE ta meen) is an antidepressant used in combination with other antidepressants for treating depression that has not responded to other therapies. 2019. Esketamine, sold under the brand name Spravato among others, is a medication used as a general anesthetic and for treatment-resistant depression. Available at: https://www.jnj.com/janssen-announces-u-s-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior (last accessed January 2021).13. These statements are based on current expectations of future events. Janssen Research & Development, LLC and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, BEERSE, BELGIUM, February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has authorised the expanded use of SPRAVATO® (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of MDD, as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.7, “Depression is more than just feeling sad, it’s a debilitating combination of symptoms that are different for each person and can progress to a point where patients may experience a psychiatric emergency,” said Professor Maurizio Pompili†, Director, University Psychiatric Clinic, Sant'Andrea Hospital, Sapienza University of Rome, Italy. 5. Visit Website, More information please phone: Patients who received Spravato treatment, plus comprehensive SOC, achieved a difference of -3.8 in depressive symptoms at 24 hours after receiving the first dose compared to placebo – a statistically significant and clinically meaningful reduction. Ionescu D, et al. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Am J Psychiatry 2015;172(10):950–966.4. Please note: This is a drug discount program, not an insurance plan. Data sources include IBM Watson Micromedex (updated 3 Mar 2021), Cerner Multum™ (updated 1 Mar 2021), ASHP (updated 3 Mar 2021) and others. This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. The cost for Spravato nasal spray 28 mg is around $687 for a supply of 2 spray, depending on the pharmacy you visit. As experts in managing specialty drug costs, Express Scripts and Accredo outperform other pharmacies with nearly 2% lower year-over-year trend.   or 877-227-3728   Hillhouse TM & Porter JH. Close. Contact Us with any questions or search this site for more information. Available at: https://www.janssen.com/emea/sites/www_janssen_com_emea/files/spravatorv_esketamine_nasal_spray_approved_in_europe_for_adults_with_treatment-resistant_major_depressive_disorder.pdf (last accessed January 2021).11. *See Additional Information section below. However, due to stock shortages and other unknown variables we cannot provide any guarantee. More information please phone: Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Johnson & Johnson Ltd. Press release on March 2019. Please see our Privacy Policy. 2013.17. DocMorris – Die Apotheke. Depression, and Major Depressive Disorder. The free Drugs.com Discount Card works like a coupon and can save you up to Spravato Prices. treat patients with SPRAVATO®. Available at: https://www.ema.europa.eu/en/medicines (last accessed January 2021).8. *Some Medicare Part D patients who cannot afford their medicines, and who meet certain financial criteria, may also be eligible for assistance. Duane Reade and 65,000 pharmacies nationwide. The reader is cautioned not to rely on these forward-looking statements. New, advanced, cutting edge treatments are highly effective and offer #hope. Lepine JP, et al. The Canadian government has placed an order with Johnson & Johnson for 10 million doses, with an option to purchase up to 28 million additional doses; on 5 March, the vaccine became the fourth to receive Health Canada approval. NDC Code(s): 50458-028-00, 50458-028-02, 50458-028-03 Packager: Janssen Pharmaceuticals Inc. SPRAVATO (esketamine) spray. Please Contact the program for more information (1-800-652-6227). Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. By intranasal administration. There are no membership fees and prescription transfers are easy. Newport DJ, et al. Nasal Spray, FDA Approved Diagnosis - See Program Website for Details. This is the story of Amelia D., a … We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Usual Adult Dose for Depression: INDUCTION PHASE: Weeks 1 to 4:-Day 1: 56 mg intranasally ONCE-Subsequent doses: 56 to 84 mg intranasally 2 times a week MAINTENANCE PHASE: Weeks 5 to 8: 56 to 84 mg intranasally … Frequently Asked Questions (FAQs) on Spravato: Nasal spray, solution. Insurers take a while to evaluate new drugs and don’t always end up covering them. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. 9. 6A71.3. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. Visit Website, More information please phone: 10. is a member of the miscellaneous antidepressants drug class and is commonly used for Call for most recent medications as the list is subject to change. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. The decision to prescribe esketamine nasal spray should be determined by a psychiatrist.7, Esketamine nasal spray was authorised by the European Commission for use in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) in adult patients with treatment-resistant major depressive disorder (TRD) in December 2019. The U.S. Food and Drug Administration (FDA) authorised esketamine nasal spray for use in conjunction with an oral antidepressant, for adults living with treatment-resistant major depressive disorder in March 2019 and for use in adults with major depressive disorder with acute suicidal ideation or behaviour in July 2020.10–12. @kprc2haleyhernandez interview on Spravato Up to a third of patients do not respond to multiple attempts at treating #depression with medication. NEW BRUNSWICK (dpa-AFX) - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)